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Addressing opioid abuse in the terminally ill
patient: To treat or not to treat?
Dr. Kavita Sharma

Disclosures
• None

Background
• Goal of hospice is to promote a peaceful death.
• Opioids are the mainstay for management of
EOL pain and dyspnea.
• Up to 25% of hospice patients have SUDs
• Hospices exempt from restrictions like PDMP.
• Most hospices do not have policies or
guidelines in place to monitor SUDs.
• Unmanaged SUDs can cause increased
suffering, mistrust, tolerance and risk for
diversion.

Challenges in the hospice patients
• Pain may be undertreated due to tolerance.
• Prior addicts may hesitate to take opioids for
fear of relapse.
• There is an overlap of both mental health and
substance abuse disorder with the use of
opioids often as a means of chemical coping:
concerns for suicide as EOL approaches.
• Risk for diversion from caregivers.

Case presentations
• Case 1. 86 yr M metastatic colon cancer with
bone mets under hospice care with a prior
history of substance abuse 20 years ago.
Patient on MS contin 15 mg BID, has sudden
escalation of symptoms and using increased
break through meds
• Case 2. 65 yr old prior Alcoholic with
metastatic lung cancer. Increased dyspnea and
agitation. Refusing narcotics for fear of
addiction

• Case 3 Mr J is a 67‐year‐old M met
pancreatic CA Uses Oxy CONTIN 40 mg twice
a day, and Oxycodone 10 mg 4 hours prn
• Recently daughter moved in to help care for
• him (he was previously living alone).
• Hospice RN notes increased pain, daughter
seems ‘‘out of it’’. The patient’s pill count is
low, indicating shortfall of 10 oxycontin and
20 oxycodone over the last 7 days.
• Mr J states his pain has been 6 to 7 on a
scale of 1 to 10 for several days.
• Refuses inpatient admit to evaluate pain

Case 4
• 57 yr old F with met pancreatic cancer
• Prognosis is days to short weeks
• Sleeping more, doing less, rarely out of bed,
complaining of more pain
• Goal is to “have her here where we can talk”
as long as possible
• Husband is very hesitant to give pain
medicines. What are the barriers?

Case 5
• 55-year-old homeless Veteran with non‐small
cell lung cancer, persistent pneumothorax
requiring a permanent chest tube
• Prior prison for drug related charges, admitted
Heroin addict in the past
• Mostly bed bound now, complains of pain
• Primary service is very suspicious of patient’s
pain complaints; he takes Dilaudid prn 4-5/day
• Plan is for transfer to a long-term nursing
facility. How to approach his pain? Barriers?

Objectives
• Discuss the recent history of pain
management and prescription drug abuse
• Identifying patients who are drug seekers vs
drug diverters
• Identify risk factors of abuse and strategies to
curb diversion
• Case discussions

Introduction: scope of the problem
• Drug OD is a leading cause of injury death in US
( more than road accidents) CDC: 115
death/day from OD
• $78.5 billion/yr in health care cost, lost
productivity, addiction Rx and criminal justice
• 116 mil Americans with chronic pain
• 21-29% of chronic pain pts misuse Rx drugs
• 4-6% transition to heroin, 80% heroin users
misused prescription opioids first
• Midwest region saw opioid OD > 70% (‘16-’17)

Introduction: scope of the problem
• 1990s drug companies spread myth “narcotics
were non addictive” increase use for non cancer
chronic pain
• 2 parallel opioid epidemics: Rx drugs and heroin
• 1996 OxyContin: coupons for one time free Rx
• US uses 83% of world’s oxycodone, 99% of
hydrocodone
• Tolerance→ frequency→ crush/snort pills to get
high→ dissolve powder and inject →black tar
heroin (cheaper, oxycodone $1/mg)

Substance abuse and chronic pain
• A systematic review of 38 studies suggests
opioid misuse rates of 21% to 29% and
addiction rates of 8% to 12% in patients with
chronic pain
• Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der
Goes DN. Rates of opioid misuse, abuse, and addiction in
chronic pain: a systematic review and data synthesis. Pain.
2015;156(4):569-576.

Prescribing opioids at EOL
• As many as 71% of CA pts fear addiction and
undertake/skip doses
• This can be a barrier to adequate symptom
control identified by hospice RN
• 25-33% under‐report pain symptoms due to
fear of addiction
• The number who refuse medications for fear
of relapse is unknown

Concept of “total pain”

Prescribing opioids at EOL
• 40% of spouses don’t think opiates should be
taken routinely
• 25% of caregivers underestimate/minimize
symptoms because they fear addiction
• Health care providers have biases against
‘addicts’ that greatly impact care
• Diversion is often not addressed
• RNs often discount pain reports and
under‐treat pain in patient’s they suspect of
substance abuse

Opioids
• Opioids bind to opiate receptors in specific
areas within the reward pathway (including
the VTA, nucleus accumbens, and cortex).
• Opioids also bind to areas involved in the pain
pathway (including the thalamus, brainstem,
and spinal cord).
• Binding of opioids to areas in the pain
pathway produces analgesia (decreased
perception of pain).

Poppy, Papaver
somniferum L.,

Natural opiates
• Alkaloids found in the resin of the opium
poppy :
• Morphine
• Codeine
• Thebaine

Semi-synthetic opiates
• Chemically altered derivatives of natural
opioids:
• hydromorphone,
• hydrocodone,
• oxycodone,
• oxymorphone,
• diacetylmorphine (heroin)

Synthetic opiates
•
•
•
•
•

Artificial compounds with opioid activity:
fentanyl,
methadone,
tramadol (ultram), and
propoxyphene (darvon).

Endogenous opioid peptides
• Substances produced naturally by the body:
endorphins, enkephalins, dynorphins,
endomorphins
• These bind to opiate brain receptors and play
role in emotion, motivation, attachment
behavior, response to stress and pain, control
of food intake
• Morphine is “Endorphin’s evil twin”

Addiction
•
•
•
•

Psychological dependence
Punishment is not a deterrent
Extreme compulsion is the overriding feature.
Using drugs and/or ETOH to the point of
intoxication/grossly impaired function, e.g. a
person gets arrested for drunk driving. Two
days later back on the road drunk
• Consider true addiction vs. under-treatment of
pain behavioral/family/psychological disorder
drug diversion

4 Cs of addiction
•
•
•
•
•

Loss of control over use;
continued use despite consequences;
compulsion to use;
and cravings
Addiction is a psychological and behavioral
syndrome
• “pseudoaddiction”: patients may act out
when distressed and may be seen as drug
seeking

Dependence
• Dependence: state in which body relies on a
substance for normal functioning.
• Eg: A person with a ruptured disk and severe
low back pain which is debilitating.
• Opiate pain medication reduces the pain to
the point where they can function normally
• In the presence of the substance, function
normalizes. You can be dependent but not
addicted. If you are addicted you are
dependent

Substance abuse
• A process of neuro adaptation
• Abrupt withdrawal may lead to abstinence
syndrome
• If dose reduction required, reduce by 50% q 2–
3 days
• avoid antagonists
• Eg: person uses a drug for recreational
purposes has a bad experience: OD or brush
with the law. Voluntarily decides “That’s it – I’m
through with this stuff.”

Tolerance
Reduced effectiveness to a given dose over time
More medication to get the same effect
Not clinically significant with chronic dosing
If dose is increasing, suspect disease progression
Rarely, sensitivity to a drug may increase
with repeated exposure, called reverse
tolerance.
Having high tolerance, e.g. needing high doses of a
drug is NOT addiction.

Withdrawal
• Group of negative physical/mental effects
resulting from cessation of substances by pts
who are habituated to their use.
• Symptoms may include severe cravings as
well as a group of negative physical effects
upon suddenly stopping the to which patient
has become dependent.
• Generally, severity depends on the length of
drug use and doses of drugs

Diversion
• The intentional removal of a medication from
legitimate distribution and dispensing
channels
• Also involves sharing or purchasing
prescription medications between family
members and friends or individual theft from
family and friends

“Red flags”
• Vague, non-specific description of pain
• Is the reported pain congruent with patient
history and presentation?
• Overwhelming interest in a particular
analgesic (particularly by family member)
• Resistance to change
• Pattern of running out on weekends, evenings,
when another doc is on call

Identifying patients with history of
substance abuse
• Use tools (eg, CAGE, CAGE-AID, and ASSIST
questionnaires) to identify patients with a
history of substance abuse
• Be nonjudgmental, empathetic, yet truthful
• If pts get defensive explain that the details will
ensure that you can prevent withdrawal and
prescribe the right drug to allow pain relief
and eliminate any serious adverse events.

CAGE/CAGE-AID: screening tool
1.Have you ever felt you needed to Cut down on your
drinking/ drug use?
2.Have people Annoyed you by criticizing your
drinking/ drug use?
3.Have you ever felt Guilty about drinking/ drug use ?
4.Have you ever felt you needed a drink/ drug use first
thing in the morning (Eye-opener) to steady your
nerves or to get rid of a hangover?
Two "yes" responses indicate that the possibility of
alcoholism or drug use should be investigated further

Opioid Risk Tool
Webster LR. Predicting aberrant behaviors in opioid-treated patients: Preliminary
validation of the opioid risk tool.Pain Medicine. 2005;6(6):432-442.

• Does your family have a history of substance
abuse?
• Do you have a history of substance abuse?
• Age, if between 16-45
• Do you have a history of preadolescent sexual
abuse?
• Do you have a history of psychological
disease?
• Low Risk 0 – 3 Moderate 4 – 7 High Risk > 8

The Alcohol, Smoking and Substance
involvement Screening Test (ASSIST)
• Q1 asks about which substances have ever
been used in the patients lifetime.
• Q2 frequency of substance use in the past 3
mo (indicates those that are most relevant to
current health status)
• Q3 frequency of craving to use each
substance last 3 mo.
• Q4 frequency of health, social, legal or
financial problems related to substance use in
the last 3 mo.

The Alcohol, Smoking and Substance
involvement Screening Test (ASSIST)
• Q5 frequency with which use of each
substance has interfered with responsibilities
in the past three months.
• Q6 has any one expressed concerns about pts
use of each substance
• Q7 has pt tried to cut down/stop use and
failed in that attempt, and how recently that
occurred
• Q8 has pt ever injected any substance and
how recently that occurred.

Pain management and substance abuse
• Multi-disciplinary team approach to handle
medical/psychosocial/ administrative issues
• They may be too draining for a solo provider
• High risk of relapse related to stress of chronic
illness and availability of drugs
• Evaluate and treat comorbid psyche issues
• Be mindful of tolerance in a substance abuser
• Begin with a conservative dose of and rapidly
titrate with frequent reassessments until the
patient is comfortable

Principles of prescribing opioid in
prior substance abuse
•Ensure that 1 provider manages prescriptions
•Written agreement about treatment plan, roles
and expectations of the team members and pt.
●Outline consequences of abuse or diversion
•Involve family for patient support/supervision
•Use 1 pharmacy; pharmacist is part of team,
oral medications are preferred, long acting
preferred
•If parenteral route needed, continuous subcut
infusion is the route of choice.

Principles of prescribing opioids in
prior substance abuse
●Use

non opioid adjuvants when possible
•Use non pharmacologic adjuvants when
possible (relaxation therapy, music, guided
imagery, biofeedback, etc)
•Limit the quantity of medication dispensed
•Conduct pill counts and request the return of
used transdermal patches
•Spot urine toxicology screening (consider if
suspecting diversion)

Prescription monitoring program
• New York State 1918, California-1939 (Oldest
Continuous Program)
• Oklahoma (1990) First to Require Electronic
Transmission of Data, reduced Operational
Costs, increased accuracy and timely
submissions. Enabled other States to Consider
• Nevada (1995) First to Require the Reporting
of More than Schedule II drugs (Schedules IIIV) First to provide Unsolicited Reports to
Practitioners

Final thoughts
Managing pain in a patient with a life-limiting
illness and a history of substance abuse is
complicated and challenging.
It is our moral duty to treat pain in patients with
substance abuse.
Follow a consistent set of prescribing principles
Use an interdisciplinary team approach,
consisting of palliative medicine and addiction
medicine expertise.

